MBX · MBX Biosciences, Inc.
$50.29
+3.69% last session
End-of-day data · close of 2026-10-26
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-12.7
Dividend yield
0.0%
Beta
0.10
Avg volume
1M
Employees
0K
Daily Change %
3.69%
5 Days Change
-0.34%
10 Days Change
1.37%
30 Days Change
-6.23%
60 Days Change
-20.17%
Month to Day Change
-11.07%
Year to Day Change
59.45%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MBX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-12
Latest call per bank · past 12 months
Barclays
Overweight$70.00
+39.2% vs priceUBS
Buy$60.00
+19.3% vs priceGoldman Sachs
Sell$18.00
-64.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Stifel | Maintains | Buy | $70.00 → $84.00 |
| 2026-10-02 | Guggenheim | Maintains | Buy | $88.00 → $150 |
| 2026-08-10 | Truist Securities | Maintains | Buy | $70.00 → $88.00 |
| 2026-07-29 | Mizuho | Maintains | Outperform | $57.00 → $91.00 |
| 2026-05-12 | Barclays | Maintains | Overweight | $66.00 → $70.00 |
| 2026-05-12 | Citizens | Maintains | Market Outperform | $76.00 → $86.00 |
| 2026-05-11 | Truist Securities | Maintains | Buy | $50.00 → $70.00 |
| 2026-01-28 | Barclays | Initiates | Overweight | $0.00 → $66.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 41 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 14.6% below the 50-day MA ($58.86).
- bullish: Price vs 200-day MA: Trading 11.2% above the 200-day MA ($45.23).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.02) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($17.00) and high ($70.70).
MBX Price Chart
Loading chart for MBX…
Fundamentals
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.